Agenus is expanding BOT+BAL immunotherapy at ESMO26 with 3 investigator-sponsored posters, including neoadjuvant colorectal cancer and advanced sarcoma studies.

Agenus is expanding BOT+BAL immunotherapy at ESMO26 with 3 investigator-sponsored posters, including neoadjuvant colorectal cancer and advanced sarcoma studies. The update builds on prior MSS mCRC survival data and a $340 million financing for Phase 3 colon cancer work.